Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting

References

1. ↵
   Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005;3:1597–602

   CrossRefPubMedWeb of Science
2. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233–38

   CrossRefPubMedWeb of Science
3. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13

   Abstract/FREE Full Text
4. ↵
   Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol 2006;98:18N–24N

   PubMedWeb of Science
5. ↵
   Serebruany V, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246–51

   CrossRefPubMedWeb of Science
6. ↵
   Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004;25:1903–10

   Abstract/FREE Full Text
7. ↵
   Jernberg T, Payne C, Winters K, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166–73

   Abstract/FREE Full Text
8. ↵
   Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392–96

   CrossRefPubMedWeb of Science
9. ↵
   Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005;45:1157–64

   CrossRefPubMedWeb of Science
10. ↵
    Grossmann R, Sokolova O, Schnurr A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004;92:1201–06

    PubMedWeb of Science
11. ↵
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the p2y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005;116:491–97

    CrossRefPubMedWeb of Science
12. ↵
    Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542–49

    CrossRefPubMedWeb of Science
13. Gurbel PA, Lau WC, Bliden KP, et al. Clopidogrel resistance: Implications for coronary stenting. Curr Pharm Des 2006;12:1261–69

    CrossRefPubMedWeb of Science
14. ↵
    Templin C, Schaefer A, Stumme B, et al. Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis. Clin Res Cardiol 2006;95:122–26

    CrossRefPubMed
15. ↵
    Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the prepare post-stenting study. J Am Coll Cardiol 2005;46:1820–26

    CrossRefPubMedWeb of Science
16. ↵
    Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the Wingspan stent system for the treatment of intracranial atheromatous disease: Periprocedural results. Stroke 2007;38:881–87

    Abstract/FREE Full Text
17. ↵
    Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781–88

    PubMedWeb of Science
18. ↵
    Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel multiplate(r) analyzer-comparison with two flow cytometric methods. Thromb Res 2007;121:249–58

    CrossRefPubMedWeb of Science
19. ↵
    Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–29

    PubMed
20. ↵
    Eikelboom J, Hankey G. Aspirin resistance: A new independent predictor of vascular events? J Am Coll Cardiol 2003;41:966–68

    CrossRefPubMedWeb of Science
21. ↵
    Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The verify thrombosis risk assessment (veritas) study. Thromb Res 2007;119:277–84

    CrossRefPubMedWeb of Science
22. ↵
    Mani H, Linnemann B, Luxembourg B, et al. Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets 2006;17:303–10

    PubMedWeb of Science
23. Alstrom U, Tyden H, Oldgren J, et al. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thromb Res 2007;120:353–59

    CrossRefPubMedWeb of Science
24. ↵
    Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005;51:957–65

    Abstract/FREE Full Text
25. ↵
    Ivandic BT, Schlick P, Staritz P, et al. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the p2y12 receptor. Clin Chem 2006;52:383–88

    Abstract/FREE Full Text
26. ↵
    Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the space trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: A randomised non-inferiority trial. Lancet 2006;368:1239–47

    CrossRefPubMedWeb of Science
27. ↵
    Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660–71

    CrossRefPubMedWeb of Science
28. ↵
    Jiang WJ, Wang YJ, Du B, et al. Stenting of symptomatic m1 stenosis of middle cerebral artery: An initial experience of 40 patients. Stroke 2004;35:1375–80

    Abstract/FREE Full Text
29. ↵
    SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (ssylvia): Study results. Stroke 2004;35:1388–92

    Abstract/FREE Full Text
30. ↵
    McKevitt FM, Randall MS, Cleveland TJ, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 2005;29:522–27

    CrossRefPubMedWeb of Science
31. ↵
    Serebruany VL, Malinin AI, Ziai W, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: For the Plavix Use for Treatment of Stroke (PLUTO-stroke) trial. Stroke 2005;36:2289–92

    Abstract/FREE Full Text
32. ↵
    Saha S, Berglund M, Sylven C, et al. Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. Int J Cardiol 2008;123:195–96

    CrossRefPubMed
33. ↵
    Eikelboom JW, Hankey GJ, Thom J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: A randomized crossover trial. J Thromb Haemost 2005;3:2649–55

    CrossRefPubMedWeb of Science
34. ↵
    Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742–50

    CrossRefPubMedWeb of Science
35. ↵
    Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420–25

    Abstract/FREE Full Text
36. ↵
    Tanaka KA, Szlam F, Kelly AB, et al. Clopidogrel (Plavix) and cardiac surgical patients: Implications for platelet function monitoring and postoperative bleeding. Platelets 2004;15:325–32

    CrossRefPubMedWeb of Science
37. Vats HS, Hocking WG, Rezkalla SH. Suspected clopidogrel resistance in a patient with acute stent thrombosis. Nat Clin Pract Cardiovasc Med 2006;3:226–30

    CrossRefPubMedWeb of Science
38. Glowczynska R, Malek LA, Spiewak M, et al. Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis—a case report and review of the literature. Int J Cardiol 2006;111:326–28

    CrossRefPubMed
39. Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748–52

    CrossRefPubMedWeb of Science
40. Dziewierz A, Dudek D, Heba G, et al. Inter-individual variability in response to clopidogrel in patients with coronary artery disease. Kardiol Pol 2005;62:108–17; discussion 118

    PubMed
41. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet vasp phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85–92

    CrossRefPubMedWeb of Science
42. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171–75

    Abstract/FREE Full Text
43. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783–87

    PubMedWeb of Science
44. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the Verifynow-p2y12(r) rapid analyzer: The Verify Thrombosis Risk Assessment (VERITAS) study. Thromb Res 2007;119:277–84

    CrossRefPubMedWeb of Science
45. ↵
    Lev EI, Ramchandani M, Garg R, et al. Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. J Thromb Thrombolysis 2007;24:15–21

    CrossRefPubMedWeb of Science
46. ↵
    Lepantalo A, Virtanen K, Heikkila J, et al. Limited early antiplatelet effect of 300mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004;25:467–83
47. ↵
    Gurbel PA, Cummings CC, Bell CR, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145:239–47

    CrossRefPubMedWeb of Science
48. ↵
    Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92–93

    FREE Full Text
49. ↵
    von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814–19

    Abstract/FREE Full Text
50. ↵
    Bilsel T, Akbulut T, Yesilcimen K, et al. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Heart Vessels 2006;21:102–07

    CrossRefPubMedWeb of Science